Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 393-394, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Tola, M.
Right arrow Articles by Vermes, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Tola, M.
Right arrow Articles by Vermes, I.
Related Collections
Right arrow Clinical Immunology
(Clinical Chemistry. 2002;48:393-394.)
© 2002 American Association for Clinical Chemistry, Inc.

Letters

Presence of AntiTissue Transglutaminase Antibodies as a Sign of Tissue Lesion

Marco Di Tola1, Luigi Sabbatella1 and Antonio Picarelli1a

1 Department of Clinical Sciences, University of Rome "La Sapienza", 155-00161 Rome, Italy

aAddress correspondence to this author at: Department of Clinical Sciences, Policlinico "Umberto I", University of Rome "La Sapienza", Viale del Policlinico, 155-00161 Rome, Italy. Fax 39-06-49970524; e-mail a.picarelli@flashnet.it.


To the Editor:

We read with interest the report (1) on IgG antibodies against tissue transglutaminase (tTG) in patients positive for anti-double-stranded DNA with systemic lupus erythematosus and in patients positive for anti-SSA/SSB. We agree with the authors’ hypothesis that in some autoimmune disorders, such as systemic lupus erythematosus, the content of apoptotic bodies (including tTG) could come into contact with the immune system, leading to an autoimmune response. Nevertheless, some aspects of this study require comments.

tTG, an intracellular enzyme, has recently been proposed as the major autoantigen of anti-endomysial antibodies (EMAs), and measurements of IgA anti-tTG antibodies are used in the diagnostic evaluation of celiac . . . [Full Text of this Article]


References

Gertjan van der Sluijs Veer2b and István Vermes2

2 Department of Clinical Chemistry, Medisch Spectrum, TwenteHospital Group, Enschede, The Netherlands

bAuthor for correspondence. Fax 31-53-487-3075; e-mail labmst@euronet.nl.


To the Editor:




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
D. Villalta, N. Bizzaro, E. Tonutti, and R. Tozzoli
IgG Anti-Transglutaminase Autoantibodies in Systemic Lupus Erythematosus and Sjogren Syndrome
Clin. Chem., July 1, 2002; 48(7): 1133 - 1133.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.